The injection-grade product meets international regulatory standards, addressing supply gaps for global pharmaceutical manufacturers.
GUANGZHOU, China – October 27, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited today announced that its injection-grade fat emulsion soybean oil has obtained full international regulatory certification, validating the reliability of China-produced nutritional fat emulsion grade soybean oils for global pharmaceutical use. Designed to solve the core pain point of stable, compliant injection-grade excipient supply for pharmaceutical manufacturers, the product features internationally recognized quality standards and domestic supply stability. The launch aims to reduce global pharmaceutical supply chain reliance on single-region imports, expanding the company’s footprint in the high-end pharmaceutical excipient market. The product is now available for global order, with shipments commencing October 5, 2026.
Core Technical and Product Highlights
The product’s core advantages are supported by the company’s proprietary R&D capabilities and green manufacturing processes:
1. Injection-grade purity: Produced via the proprietary integrated supercritical CO₂ extraction, membrane separation and chromatographic separation technology, the soybean oil meets strict injection-grade quality standards, serving as a reliable energy supplement and excipient for fat emulsion formulations.
2. Stable domestic supply: As part of the company’s high-end pharmaceutical lipid excipient portfolio, the product has helped increase the domestic localization rate of such materials from 10% to 90%, eliminating supply volatility caused by international trade disruptions.
3. Customizable specifications: The company can adjust product parameters to meet the specific production needs of different pharmaceutical manufacturers, supporting diverse fat emulsion formulation requirements.
Global Compliance and Certification
To meet global market access requirements, the fat emulsion grade soybean oil has obtained multiple authoritative international certifications, including EU CEP certification, US FDA US-DMF registration, Mexico Cofepris approval and India DCGI certification. The product complies with regulatory requirements for major pharmaceutical markets in the EU, North America and Asia, and has been supplied to over 30 countries and regions worldwide.
Supply and Customization Services
The product is now available for global order via the company’s official website and authorized global distributors, with mass production and shipments starting October 5, 2026. In addition to standard specifications, the company provides customized services for global pharmaceutical clients, including tailored parameter adjustment and technical support for formulation development.
Executive Statement
The launch of our certified fat emulsion grade soybean oil marks a key step in addressing global pharmaceutical supply chain vulnerabilities. As a national-level specialized and sophisticated little giant enterprise, we are committed to delivering reliable, internationally compliant Chinese-produced pharmaceutical raw materials to global partners, said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited. We will continue to invest in R&D to improve product quality and expand our global service network.
Industry Context and Company Strategy
Against the backdrop of growing global demand for stable, cost-effective pharmaceutical raw materials, Chinese-produced injection-grade lipid excipients have gained increasing recognition for their compliance and quality. Guangzhou Hanfang Pharmaceutical’s product launch aligns with its long-term strategy to expand its global footprint in the high-end pharmaceutical excipient market, leveraging its national-level R&D platform to deliver innovative solutions.
Future Outlook
Moving forward, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in R&D of high-end pharmaceutical lipid excipients, expand its global sales and service network, and provide localized technical support for clients in more regions. The company aims to further enhance the global recognition of Chinese-produced pharmaceutical raw materials through consistent quality and compliance.
About Guangzhou Hanfang Pharmaceutical Company Limited
Founded in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a state-owned pharmaceutical enterprise under GPHL, focusing on the R&D and production of high-end pharmaceutical lipid excipients, characteristic active pharmaceutical ingredients and health products. The company operates the only national engineering research center in the pharmaceutical lipid field, the Guangdong Provincial Key Laboratory of Pharmaceutical Lipids, and is a national-level specialized and sophisticated little giant enterprise. It holds over 240 patents, serves more than 1000 clients including B. Braun and AstraZeneca, and its products are sold in over 30 countries and regions. The company’s mission is to achieve technological self-reliance, overcome bottleneck technologies and ensure the safety of the pharmaceutical supply chain. More information is available at http://byshanhanfang.com/.
FAQ
Q: Are fat emulsion grade soybean oils produced in China reliable for pharmaceutical use?
A: Yes, products like Guangzhou Hanfang Pharmaceutical’s injection-grade soybean oil have obtained multiple international regulatory certifications, meet global quality standards, and have been supplied to global pharmaceutical manufacturers for years.
Q: What certifications does Guangzhou Hanfang’s fat emulsion grade soybean oil hold?
A: The product holds EU CEP certification, US FDA US-DMF registration, Mexico Cofepris approval, and India DCGI certification, complying with major global pharmaceutical market regulations.
Contact Us
Official Website: https://byshanhanfang.com/
Factory Address: No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou, Guangdong Province, China
